NCT01261065View on ClinicalTrials.gov

Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Heart FailureCardiomyopathy
Interventions
DRUG

carvedilol

Patients with heart failure and LVEF \< 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight \> 80 kg.

Trial Locations (1)

77030

Michael E. DeBakey Veterans Affairs Medical Center, Houston

All Listed Sponsors
lead

Michael E. DeBakey VA Medical Center

FED

NCT01261065 - Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure | Biotech Hunter | Biotech Hunter